- Home
- NUVL vs LSTR Comparison
NUVL vs LSTR Comparison
Compare NUVL & LSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- LSTR
- Stock Information
- Founded
- NUVL 2017
- LSTR 1991
- Country
- NUVL United States
- LSTR United States
- Employees
- NUVL N/A
- LSTR N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- LSTR Trucking Freight/Courier Services
- Sector
- NUVL Health Care
- LSTR Industrials
- Exchange
- NUVL Nasdaq
- LSTR Nasdaq
- Market Cap
- NUVL 5.6B
- LSTR 5.4B
- IPO Year
- NUVL 2021
- LSTR 1993
- Fundamental
- Price
- NUVL $70.46
- LSTR $151.93
- Analyst Decision
- NUVL Strong Buy
- LSTR Hold
- Analyst Count
- NUVL 10
- LSTR 13
- Target Price
- NUVL $113.10
- LSTR $163.90
- AVG Volume (30 Days)
- NUVL 594.2K
- LSTR 410.4K
- Earning Date
- NUVL 05-08-2025
- LSTR 04-29-2025
- Dividend Yield
- NUVL N/A
- LSTR 2.25%
- EPS Growth
- NUVL N/A
- LSTR N/A
- EPS
- NUVL N/A
- LSTR 5.51
- Revenue
- NUVL N/A
- LSTR $4,834,055,000.00
- Revenue This Year
- NUVL N/A
- LSTR $6.12
- Revenue Next Year
- NUVL N/A
- LSTR $9.32
- P/E Ratio
- NUVL N/A
- LSTR $27.49
- Revenue Growth
- NUVL N/A
- LSTR N/A
- 52 Week Low
- NUVL $61.80
- LSTR $144.13
- 52 Week High
- NUVL $113.51
- LSTR $196.86
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- LSTR 47.85
- Support Level
- NUVL $67.47
- LSTR $146.81
- Resistance Level
- NUVL $77.93
- LSTR $151.45
- Average True Range (ATR)
- NUVL 3.15
- LSTR 3.67
- MACD
- NUVL -0.44
- LSTR 0.67
- Stochastic Oscillator
- NUVL 26.88
- LSTR 86.19
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About LSTR Landstar System Inc.
Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage (90% of revenue). Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.